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Congestive heart failure as an indication for continuous renal mmol/liter), potassium 5.9 mmol/liter (3.5 to 5.0 mmol/
replacement therapy. Continuous venovenous hemofiltration liter), and blood urea nitrogen 55 mg/dl (,28 mg/dl).
(CVVH) is the most widely used renal replacement therapy The mean arterial pressure was 80 mm Hg, heart ratefor the treatment of critically ill patients with acute renal failure
was 90 beats per minute, and the central venous pressureon the intensive care unit. Whether or not congestive heart
was 24 mm Hg. Initial treatment with catecholaminesfailure is an indication for CVVH is controversial and needs
to be discussed. Therefore, we present a patient with congestive and high doses of furosemide (1000 mg in 6 hr) in order
heart failure who was treated successfully with CVVH. to stimulate renal fluid excretion was unsuccessful; there-
fore, the patient was treated with continuous venovenous
hemofiltration (CVVH) for 10 hours (Fig. 1). A lactate-
While continuous venovenous hemofiltration (CVVH) buffered solution (45 mmol/liter) was applied at a filtra-
is the most often used renal replacement therapy for tion rate of 1000 ml/hr and a substitution rate of 750 ml/hr,
critically ill patients with acute renal failure, its use for resulting in a negative fluid balance of 250 ml/hr. In order
those with severe congestive heart failure remains a topic to reduce the preload, a maximal ultrafiltration volume
for discussion. After the initial cardiogenic shock, acute of 2,500 ml was reached. Immediately after the beginning
renal failure and impaired renal perfusion often occur, of CVVH therapy, the patient’s diuresis returned. The
and if renal function is not swiftly restored then multi- amount of catecholamines administered was reduced sig-
organ damage and death can result. These decompen- nificantly, and symptoms of CHF such as dyspnea and
sated patients are usually resistant to diuretics and have edema improved. The central venous pressure (CVP)
a massive fluid overload; their prognosis is poor. This fell to a minimum of 19 mm Hg. The mean arterial
article examines one case in light of the current literature, pressure increased to 120 mm Hg, and the heart rate was
and discusses therapeutic options for the management unchanged. The patient developed a sufficient diuresis
of congestive heart failure patients who are in critical care. under further diuretic therapy, and renal function re-
We report the case of a 40-year-old male who was turned to normal (creatinine 1.1 mg/dl) after four days.
admitted to the intensive care unit because of severe The hemodynamic situation of the patient under a therapy
congestive heart failure (CHF). The patient suffered with dobutamine in a low dose intravenous (15 mg/hr)
from dilative cardiomyopathy as a consequence of viral and angiotensin-1 receptor blocker (Lorzaar) 25 mg/day
myocarditis eight years earlier. On admission, the patient orally was stable, but because of the severe reduction
presented with severe hypotension and dyspnea, periph- of cardiac function (cardiac index 1.7 liter/min/m2) by
eral edema, and liver and renal function impairment. dilative cardiomyopathy, the patient underwent a suc-
The relevant laboratory values were as follows: aspartate cessful heart transplantation two months later.
aminotransferase (AST) 410 U/liter (,17 U/liter), ala- This case report presents a patient with acute decom-
nine aminotransferase (ALT) 260 U/liter (,23 U/liter), pensation of CHF by cardiomyopathy. The patient had
bilirubin 5.4 mg/dl (,1.1 mg/dl), alkaline phosphatase acute renal failure in the beginning of onset, and suffered
(ALP) 244 U/liter (,180 U/liter), serum creatinine 2.7 from liver congestion and pulmonary edema. He needed
mg/dl (1.2 mg/dl), sodium 135 mmol/liter (135 to 145 catecholamines to stabilize the hemodynamic situation,
but did not respond to large doses of diuretics. Early
use of CVVH led to an increase in urinary output, raisedKey words: acute renal failure, heart failure, continuous venovenous
hemofiltration, renal replacement therapy. the mean arterial pressure, and relieved the symptoms.
Thus, CVVH led to an improvement of cardiac function 1999 by the International Society of Nephrology
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Fig. 1. Time course of continuous venovenous he-
mofiltration (CVVH) treatment in a patient with
severe congestive heart failure and massive volume
overload. Symbols are: ( columns) urine output;
(r) mean arterial blood pressure; (j) central ve-
nous pressure.
as well as renal function. CVVH therapy led to a stabili- state with peripheral edema, pleural effusion, and edema
of the lung, and they do not respond to diuretic therapy.zation of the patient and prevented further deterioration
Thus, they are in a state of decompensated heart failureof organ function.
with a high sodium and water retention as a neurohu-
moral response to low cardiac output. When these pa-
CONTINUOUS VENOVENOUS tients show no improvement under therapy with cate-
HEMOFILTRATION IN SEVERE CONGESTIVE cholamines in high doses and a maximum of diuretic
HEART FAILURE therapy, hemofiltration might be beneficial.
In cardiogenic shock after massive myocardial in- The use of hemofiltration as an intermittent [4–7] or
farction or low-output syndrome caused by cardiomyop- a continuous [8–10] therapy in patients with severe CHF
athy, acute renal failure and loss of diuresis caused by has been described by several authors. In a study of
renal perfusion impairment is frequent. This leads to arteriovenous hemofiltration, Kramer et al included pa-
fluid and electrolyte imbalance and the accumulation of tients with CHF and overhydration who were resistant
toxic metabolites, which also further suppresses cardiac to diuretic therapy [11]. Next to arteriovenous hemofil-
function. These factors contribute to marked cardiovas- tration [6, 11], the venovenous approach is the most
cular instability. In these patients, the performance of widely used technique [6, 8, 9]. Most studies are patient
intermittent hemodialysis is not recommended because surveys [5, 6, 12] or case reports [10]. Only a few studies
of severely compromised hemodynamics. Therefore, exist in which patients were systematically investigated
CVVH is administered in order to remove excess body [8, 13–16]. Patients with CHF were treated for a short
fluid, to correct metabolic acidosis, and to eliminate ure- period of time [4, 8, 9, 13, 14] or for a long period up to
mic metabolites. As a result, an improvement of the several months [6, 7, 12]. The effects of hemofiltration in
cardiovascular situation is observed. Therefore, CVVH CHF included: a relief of the patients’ symptoms [4, 6, 9],
in patients with cardiogenic shock and acute renal failure a decrease of central venous or right atrial pressure
is the first choice for renal replacement therapy [1]. [4, 5, 9], and a lowered capillary wedge pressure [4, 5, 9],
Whether or not CVVH is indicated even in an earlier which led to an increase of urinary output [4, 13, 16].
state of cardiac dysfunction, when renal failure is im- Use of hemofiltration for a long period of time led to
pending and multiorgan dysfunction caused by low car- weight reduction, a reduced hospital stay, or reduced
diac output might be prevented, is of specific interest. diuretic treatment [12]. All of these studies showed the
Congestive heart failure is characterized by low car- long-lasting effect of the hemofiltration and that the pa-
diac output and leads to sodium and water retention tients were able to respond to pharmacological therapy
[2], neuroendocrine activation, and constriction of the again.
peripheral circulation. Therapeutic options include phar- In patients with moderate heart failure, it was shown
macological therapies, the use of mechanical devices, that a single session of ultrafiltration led to an improve-
and heart transplantation [3]. The type of treatment ap- ment of hemodynamics, including a significant increase
plied to a patient depends on the symptoms, the cause of the cardiac index [14]. Furthermore, compared to an
for heart failure, and the time of progression. There are infusion of furosemide, the markers reflecting neurohu-
moral activity returned to normal by ultrafiltration. Thesome patients who appear to be in a decompensated
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removal of 1.6 liters by ultrafiltration compared to a sustained break of the vicious cycle of neurohumoral
activity and water and sodium retention are achieved.removal of 1.6 liters by diuretics led to a sustained de-
crease in of the levels of norepinephrine, renin, and aldo- In some of the studies cited, the patients had no renal
failure, which means they had oliguria but no anuriasterone [15]. One single intermittent hemofiltration ther-
apy with the filtration of 2983 6 1228 ml increased with a creatinine of less than 2.0 mg/dl. The point is that
renal failure is more a question of definition and time.urinary output and sodium excretion and led to a fall in
norepinephrine levels, effects that persisted for 24 to 48 In reality, in most patients, prerenal azotemia is present
or acute renal failure is impending because of low cardiachours [13]. Thus, these studies showed surprisingly that
the effect of hemofiltration was superior to the effect of output and decreased renal plasma flow. However, ac-
cording to current literature, it seems that an early startdiuretic therapy [13–16].
The outcome of patients with heart failure grade IV of water and sodium removal by hemofiltration is best
[8, 9]. As in the presented case, an early start of hemofil-according to the New York Health Association (NYHA)
was poor in most of the studies, but the parameters tration prevents further multi-organ deterioration, stabi-
lizes cardiac function, improves renal function, and, inrelated to poor prognosis before starting CVVH therapy
were oliguria for more than 15 hours or a creatinine of some cases, it might prevent the intubation and mechani-
cal ventilation of the patient. Thus, hemofiltration inmore than 4.0 mg/dl [9]. The patient with the best out-
come had the shortest time of oligo-anuria and had the CHF is indicated by fluid overload resistant to diuretics
alone and not as usual by azotemia, high potassium lev-greatest benefit from the therapy [9]. CVVH started pre-
operatively in patients with severe heart failure and un- els, or acid-balance disorders. It is not yet clearly under-
stood whether the beneficial effect of CVVH in CHF isdergoing cardiopulmonary bypass surgery resulted in an
improvement of all hemodynamic variables during he- a single effect of preload reduction or the effect of the
reduction of toxic metabolites [8], like a myocardial de-mofiltration and the restoration of renal function [8].
This suggests that an early start of CVVH in CHF is pressant factor [18]. Although many CHF patients have
been treated with HF, there are no controlled studiesnecessary to improve the patient’s chance for survival.
on this topic. While our reported patient showed anThe results of these studies show that CVVH treat-
improvement with this therapy, the overall prognosis ofment is a useful tool to interrupt further fluid retention
these patients remains poor.and to re-establish a sufficient renal function. Respon-
siveness to diuretic therapy is restored and diuresis re-
turns. CVVH is especially useful in patients with severely CONCLUSIONS
compromised cardiac function and the beginning of renal
Hemofiltration is a therapeutic option for the manage-function impairment. It leads to an immediate reduction
ment of cardiac failure and is ideal to bridge the timein preload, and therefore, renal perfusion is restored.
to transplantation. In some cases, hemofiltration mayCVVH may also be employed in patients with severely
help to prolong the lifespan of patients with CHF. Thecompromised cardiac function who are awaiting a heart
important fact is that renal replacement therapy has totransplantation in order to carefully reduce excess body
be started early to prevent further organ damage and tofluid and stabilize the patient before the heart surgery.
prevent further multi-organ dysfunction.For this reason, CVVH was included in the guidelines
Future studies should focus the question of whetherof therapeutic options for the treatment in severe heart
the prognosis of patients with CHF can be improved underfailure by the Task Force of the Working Group on Heart
application of continuous renal replacement therapies.Failure of the European Society of Cardiology [3].
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